Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/ Pharmacodynamics, and Antitumor Activity of TGI-6 as Monotherapy in Subjects With Locally Advanced/Metastatic Solid Tumors

NCT06374173 is registered in ClinicalTrials.gov with Hefei TG ImmunoPharma Co., Ltd. as lead sponsor.

NCT NCT06374173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06374173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/ Pharmacodynamics, and Antitumor Activity of TGI-6 as Monotherapy in Subjects With Locally Advanced/Metastatic Solid Tumors
Lead sponsor
Hefei TG ImmunoPharma Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
January 3, 2024
Completion date
December 31, 2027
Enrollment
123 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors